99,240 Shares in Eli Lilly and Company $LLY Bought by Private Advisor Group LLC

Private Advisor Group LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 99,240 shares of the company’s stock, valued at approximately $114,827,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. PCG Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 7.8% in the 3rd quarter. PCG Wealth Advisors LLC now owns 250 shares of the company’s stock valued at $290,000 after purchasing an additional 18 shares during the last quarter. Hartford Funds Management Co LLC raised its stake in Eli Lilly and Company by 3.1% during the third quarter. Hartford Funds Management Co LLC now owns 3,382 shares of the company’s stock worth $3,916,000 after buying an additional 101 shares during the last quarter. Focus Advisor Solutions LLC raised its stake in Eli Lilly and Company by 69.9% during the third quarter. Focus Advisor Solutions LLC now owns 23,763 shares of the company’s stock worth $27,497,000 after buying an additional 9,776 shares during the last quarter. Bluebird Wealth Management LLC lifted its holdings in Eli Lilly and Company by 1.0% in the third quarter. Bluebird Wealth Management LLC now owns 1,882 shares of the company’s stock valued at $2,178,000 after buying an additional 19 shares during the period. Finally, Alpha Financial Partners LLC lifted its holdings in Eli Lilly and Company by 4.4% in the third quarter. Alpha Financial Partners LLC now owns 714 shares of the company’s stock valued at $826,000 after buying an additional 30 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of research analyst reports. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Morgan Stanley raised their target price on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, TD Cowen reiterated a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,422.00.

View Our Latest Report on LLY

Recent Eli Lilly and Company Headlines

Investors following LLY have been watching these headlines:

  • Positive Sentiment: Health Canada also approved Lilly’s GLP-1 pill for weight loss, adding a potential growth opportunity in the obesity market. Article: Health Canada approves Eli Lilly’s GLP-1 pill for weight loss
  • Positive Sentiment: Lilly is expanding oncology research through its planned acquisition of Calytrix Bio, potentially worth up to $1.5 billion, and a Stipple Bio collaboration that could reach $5.9 billion. The deals add cancer programs and precision-therapy research, though much of their value depends on future milestones and development. Article: Eli Lilly expands its oncology research platform
  • Negative Sentiment: State Street Health Care SPDR (XLV) sold its entire portfolio on Nov. 17, including $42.3 million of LLY shares. This is a reported fund outflow, although the fund sold all 60 holdings rather than singling out Lilly. Article: What State Street Health Care SPDR sold

Eli Lilly and Company Trading Down 2.4%

LLY opened at $1,380.92 on Thursday. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,475.25. The firm has a market capitalization of $1.30 trillion, a PE ratio of 44.82, a P/E/G ratio of 1.69 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The company’s 50-day moving average is $1,258.86 and its 200 day moving average is $1,115.99.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company’s quarterly revenue was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $7.02 EPS. As a group, research analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.